Indian Gene + Cell Therapy Facility MEP — USFDA 21 CFR 1271 + EU EMA Annex 1 + ICH Q5 + ImmunoACT
A 200 patient-doses/year Indian autologous CAR-T facility (ImmunoACT-class) demands ₹824 Cr MEP capex with apheresis room + Grade A LAF in B viral-vector transduction + closed-system bioreactor + cryopreservation + LIMS chain-of-identity + Class II BSC. USFDA 21 CFR 1271 + EU EMA Annex 1 + ICH Q5 + Schedule M + FACT-JACIE govern. Indian CAR-T cost ₹25L/patient vs international ₹3 Cr+. Three failures: open vs closed-system inconsistent, chain-of-identity manual paper instead of LIMS + 21 CFR 11, cryopreservation in liquid LN2 instead of vapour-phase causing contamination.
Indian gene + cell therapy facility framework
India advanced therapy — IndImmuno (Bharat Biotech) + ImmunoACT (autologous CAR-T) + ICGEB + Mylab + Indian Council of Medical Research IND filings. Cell + gene therapy (CGT) demands Grade A LAF + isolator + biosafety cabinet + viral-vector closed-system + cleanroom-in-cleanroom architecture. Standards stack — USFDA 21 CFR 1271 (HCT/P) + EU GMP Annex 1 + Schedule M 2023 + ICH Q5A + Q5D + India RCGM + DBT + CDSCO + ATMP-specific guidelines + USP 1071 + 1079 + 1090.
Autologous CAR-T cell therapy facility MEP scope — 200 patient-doses/year
| Zone | Grade | Function | Capex (₹ Cr) |
|---|---|---|---|
| Apheresis collection room | D | patient blood collection | 22 |
| Sample reception + cryostorage | — | -150°C LN2 | 45 |
| Open processing — Grade A LAF in B | A in B | viral-vector transduction | 185 |
| Closed-system bioreactor | C | CGT expansion | 125 |
| Fill-finish (Grade A in B) | A in B | autologous fill | 85 |
| Cryopreservation (-196°C controlled-rate) | — | — | 55 |
| Quality control (sterility + flow cytometry + potency) | — | USP 1116 + ICH Q5 | 85 |
| LIMS + chain-of-identity + chain-of-custody | — | — | 25 |
| Biosafety cabinet (Class II Type A2) | — | — | 35 |
| Decontamination (VHP) | — | — | 22 |
| HVAC + 100 % OA + 25 ACH + HEPA | — | — | 85 |
| Pure utilities (WFI + pure steam + medical N2) | — | — | 55 |
| Total CGT facility | — | — | 824 |
Three Indian CGT facility MEP failures
- Open vs closed-system not consistent — autologous CGT requires either fully-closed system OR Grade A LAF in B at every open step. Indian facilities sometimes mix — fails USFDA + EMA cGMP inspection.
- Chain-of-identity + chain-of-custody documentation gaps — autologous CGT cannot tolerate sample mix-up = patient harm. Specify LIMS with barcode + electronic-signature + 21 CFR Part 11 compliance. Indian R&D often paper-based + manual.
- Cryopreservation controlled-rate freezing + vapour-phase LN2 — viable cell preservation requires -1°C/min cooling rate + < -150°C storage in vapour-phase LN2 (cross-contamination risk in liquid). Indian facilities sometimes use liquid LN2 = contamination + thawing failure.
- USFDA 21 CFR 1271 — Human Cells Tissues + Cellular + Tissue-Based Products (HCT/P).
- EU EMA GMP Annex 1:2022 + ATMP Guideline 2018.
- Schedule M 2023 (India) + CDSCO Clinical Trial Rules.
- ICH Q5A + Q5D — Cell Bank + Viral Safety.
- USP 1071 + 1079 + 1090 — Sterility + Distribution + Cellular Products.
- India RCGM + DBT Recombinant Cell + Gene Therapy Guidelines 2024.
- FACT-JACIE Standards 2024 (international CGT).
- USFDA 21 CFR Part 11 — Electronic Records + Signatures.